ANZCTR search results

This study will assess how a sample group of approximately 4000 elderly patients are being screened and daignosed for osteoporosis.

There is a well known association between salt intake and blood pressure. This study will help in the understanding of whether education/information alone enables people to choose a low salt diet if they wish to do so

Hypothesis - central venous pressure measurement by compression sonography correlates with central venous pressure measurement by invasive methods

Research hypotheses: People with chronic low back pain are likely to prefer and participate in exercise programs that are designed with consideration of their preferences, circumstances and past experiences. Research Aims: 1. The primary aim of this study is to test the effect of a mechanism for systematically recruiting information about patient exercise program preferences using a questionnaire developed from previous focus group research on exercise adherence and health outcomes compared to designing an exercise program without the assistance of the questionnaire 2. The secondary aims are to obtain feedback from clinicians who have utilized the instrument to assist with instrument refinement. Research Questions: 1. Does participant-informed exercise design improve program engagement and adherence? 2. Does participant informed exercise design improve health outcomes of exercise programs for chronic low back pain and other musculoskeletal conditions?

Objective: The current trial examined whether a specific cognitive behavioral treatment package was more efficacious in treating childhood anxiety disorders than a non-specific support package. Method: One-hundred and twelve children (ages 7-16 years) with a principal anxiety disorder were randomly allocated to either a group cognitive behavioral treatment (CBT) program or a control condition (Group Support and Attention; GSA). Results: Overall, results showed that CBT was significantly more efficacious compared to the GSA condition: 68.6% of children in the CBT condition did not meet diagnostic criteria for their principal anxiety diagnosis at 6 month follow-up compared to 45.5% of children in the GSA condition. The results of the child- and parent-completed measures indicated that whereas mothers of CBT children reported significantly greater treatment gains than mothers of GSA children, children reported similar improvements across conditions. Conclusions: Specific delivery of cognitive behavioral skills is more efficacious in the treatment of childhood anxiety than a treatment that includes only non-specific therapy factors.

This trial will use a new method of treating lymphoma using a therapy derived from a person’s Killer T cells. These Killer T cells are taken from a person's blood and grown in a test tube to increase the number of these cells that are specifically active against the lymphoma cells. The cells are then given to the patient by intravenous infusion with the aim of killing the lymphoma cells. Potentially this treatment will help to kill the residual/recurrent tumour that is present after other lymphoma treatment and reduce the chance of the tumour recurring.

This study aims to identify protein markers that are suitable for allowing early detection of ovarian cancer. Who is it for? You can join this study if you have either: (1) known ovarian cancer diagnosed from a previous pathology specimen. (2) an ovarian mass which may be benign or malignant. and you will be having surgical removal of either your ovary or ovaries (oophorectomy or ovariectomy) or your uterus (hysterectomy). Trial details: Participants will be requested to donate biological samples: blood, tissue, ascites (peritoneal cavity fluid), urine and uterine lavage (washings). This does not interfere with other diagnostic tests, or with the required medical or surgical treatment. Surgery will be performed in exactly same way, as if the samples had not been collected. Detection of ovarian cancer at its earliest stages provides a good prognosis for full recovery; however survival diminishes greatly when the cancer spreads beyond the ovary. Current ovarian cancer markers lack the accuracy needed to provide a suitable early detection test. This study uses new procedures to identify a number of candidate blood protein markers produced by ovarian cancers which may be suitable as early cancer markers.

The aim of this project is to investigate the relationship between the spine, rib cage and associated muscles and lung function following the administration of spinal manipulation and exercise. The project will be conducted on healthy people with a previous history of respiratory disease who have either normal or below normal current lung function.

A 14 week study investigating whether whole grain rich diets have beneficial effects on the markers of metabolic syndrome compared to diets rich in refined grains. There will be 2 different diets of 6 weeks each duration. Participants will be required to follow one diet for 6 weeks, then a 2 week "Wash out" (normal eating pattern) before following the second diet for 6 weeks. The study will compare the effect of a diet rich in whole grain foods versus a diet rich in refined grain foods on glucose levels and clot breakdown.

This study is an Open label extension study following a double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy and safety of adjunctive zonisamide in primary generalized tonic-clonic seizures. Zonisamide is an investigational drug. RESEARCH OBJECTIVES To assess the long-term safety and efficacy of zonisamide in subjects with primary generalized tonic-clonic seizures. STUDY DESIGN Subjects who completed Visit 7 of the double blind study (E2090-E044-315) will be invited to enter into this extension study. After provision of informed consent at this visit, the study will start with a double-blind Titration Period (to avoid unblinding of study E2090-E044-315). Subjects treated with zonisamide in study E2090-E044-315 will continue on the same dose of zonisamide while they are being started with placebo. Subjects treated with placebo in study E2090-E044-315 will continue to take placebo and additionally be uptitrated with zonisamide up to the dose level that subjects were treated with at the end of study E2090-E044-315 (up to a maximum of 400 mg or 350 mg (6 mg/kg) if the subject is less than 12 years of age). For those subjects in the placebo group, dosing with zonisamide will start with a dose of 1 mg/kg (subjects < 12 years) or 50 mg (subjects = 12 years). The dose of zonisamide is up titrated in the same schedule as in study E2090-E044-315. The Titration Period will last four to seven weeks. Subjects who completed the double blind study on a maximum tolerated dose of 200 mg (or 4 mg/kg for subjects <12 years) will complete titration more quickly than other subjects i.e within 3 weeks, but will be maintained on the Week 3 dose for another week during the Titration Period in order to maintain the blind, before entering the open label Maintenance Period. In subjects who do not tolerate this titration, both the blinded maintenance dose from study E2090-E044-315 and the transition titration dose introduced in E2090-E044-316 will be downtitrated to 100 mg (if adult or child < 12 years and weight >28 kg) or 50 mg (if child < 12 years and weight 20-28 kg). When this dose is reached, open-label zonisamide will be started at the age/weight-appropriate starting dose, if this is decided to be in the best interest of the subject by the investigator. After this period subjects who completed the uptitration will be taking the maintenance dose of zonisamide so the study will become in effect open label and a switch is made to open-label maintenance medication. The dose of open-label zonisamide through the remainder of the study will be flexible at the discretion of the investigator and based on tolerability and efficacy. Trial medication will be taken once daily in the evening throughout the study.